Discovery of novel nonpeptide allosteric inhibitors interrupting the interaction of CDK2/cyclin A3 by virtual screening and bioassays

详细信息    查看全文

• 作者：Yutong Hu^a ; ^b ; ^&dagger ; ; Shuai Li^b ; ^&dagger ; ; Fang Liu^c ; ^&dagger ; ; Lv Geng^b ; Xiaohong Shu^a ; ^{xiaohong_shu@dlmedu.edu.cn" class="auth_mail" title="E-mail the corresponding author} ; Jian Zhang^b ; ^{jian.zhang@sjtu.edu.cn" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Cell cycle ; Allosteric regulation ; CDK2 allosteric inhibitors ; Virtual screening
• 刊名：Bioorganic & Medicinal Chemistry Letters
• 出版年：2015
• 出版时间：1 October 2015
• 年：2015
• 卷：25
• 期：19
• 页码：4069-4073
• 全文大小：1227 K

文摘

Serine/threonine-specific cyclin-dependent kinases (CDKs) are key regulatory elements in eukaryotic cell cycle progression, and the dysregulation of CDKs has been implicated in cancers. Therefore, CDKs have been identified as anti-cancer targets for the development of small-molecule drugs. In this Letter, virtual screening and biological evaluation were performed to identify novel lead structures that allosterically disrupt the interaction between CDK2 and cyclin A3, which are directed toward a noncatalytic binding pocket of CDK2. Ultimately, B2 was identified as exhibiting superior CDK2/cyclin A3 inhibition activity. In addition, our results indicated that B2 exhibited antiproliferative activities against a broad spectrum of human cancer cell lines. Significantly, B2 certainly interrupted the interaction between CDK2 and cyclin A3 and exhibited a concentration-dependent trend. In summary, our results suggest that B2 is the first effective allosteric chemical small-molecule CDK2 inhibitor to be discovered, and further lead optimization may result in a series of novel anti-CDK2 agents.